Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia;Efecto comparativo de policosanol con dos inhibidores de la HMG-CoA reductasa en el tratamiento de la hipercolesterolemia tipo II

Revista Medica de Chile

Volumn 127, Issue 3, 1999, Pages 286-294

  Prat M, Hernán ^a   Román A, Oscar ^a   Pino O, Eugenia ^a  

^a Químico Farmacéutico ^*

Author keywords

Anticholesteremic agents; Hypercholesterolemia; Lovastatin; Policosanol; Simvastatin

Indexed keywords

FATTY ALCOHOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; MALE; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FATTY ALCOHOLS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYPERLIPOPROTEINEMIA TYPE II; LOVASTATIN; MALE; MIDDLE AGED; SIMVASTATIN;

EID: 0033091942     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. STAMLER J, WENTWORTH D, NEATON JD FOR THE MRFIT RESEARCH GROUP. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356222 primary screenings of the Multiple Risk Factors Intervention Trial. JAMA 1986; 256: 2-823.
2. CASTELLI WP, GARRISON RJ, WILSON PWF, ABBOT RD, KALOUSDIAN WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986; 256: 2835-8.
3. LIPID RESEARCH CLINICS PROGRAM. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64.
4. LIPID RESEARCH CLINICS PROGRAM. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-74.
5. MANNINEN V, ELO MO, FRICK MH, HAAPA K, HEINONEN OP, HEINSALMI P ET AL. Lipid alterations and decline in the incidence of coronary heart disease in the Heksinki Heart Study. JAMA 1988; 260: 641-51.
6. BROWN G, ALDERS JJ, FISHER LD, SHAEFER SM, LIN JT, KAPLAN C ET AL. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-98.
7. SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP. Randomised trial of cholesterol-lowering in 4.444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994; 344: 1383-94.
8. SHEPERD J, COBBE SM, CHRISTOPHER G, LORMER AR, MCFARLANE PW, MCKILLON JH ET AL. For the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995; 333: 1301-51.
9. HJERMANN I, VELVE BYRE K, HOLME L, LEREN P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Lancet 1981; 2: 1303-10.
10. NATIONAL CHOLESTEROL EDUCATION PROGRAM. Report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 1993; 269: 3015-23.
11. MABUCHI H, HABA T, TATAMI R, MIYAMOTO S, SAKAI Y, WAKASUGI T ET AL. Effects of an inhibitor of HMG CoA reductasa on serum lipoproteins and Ubiquione 10 levels in patients with familial hypercholesterolemia. N Engl J Med 1981; 305: 478-82.
12. SHEPERD J. Pharmacologic modulation of plasma cholesterol levels, in European Lipoprotein Club Ed. The first ten years. Glasgow. UK 1987; 127-31.
13. LOVASTATIN STUDY GROUP II. Therapeutic response to lovastatin (Mevinolin) in non familial hypercholesterolemia. JAMA 1986; 256: 829-34.
14. ILLINGWORTH DR. An overview of lipid-lowering drugs. Drugs 1988; 36: 63-71.
15. TIKKANEN M, HELVE E, KAARSALA E, LEHTONEN A, MALBERG W, OKSA H ET AL. Comparison between lovastatin and gemfibrozil in the treatment of primary liypercholesterolemia. The finnish multicenter study. Am J Cardiol 1988; 62: 35J-43J.
16. TOBERT JA, SHEAR CL, CHREMS A, MANTELL G. Clinical experience with lovastatin. Am J Cardiol 1990; 65: 23F-26F.
17. TODD PA, GOA KL. Simvastatin: a review of its pharmacological properties and therapeutical potential in hypercholesterolemia. Drugs 1990; 40: 583-607.
18. MITCHEL YB. The long-term tolerability profile of lovastatin and simvastatin. Atherosclerosis 1992; 97: S33-S39.
19. THE SIMVASTATIN PRAVASTATIN STUDY GROUP. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol 1993; 71: 1408-14.
20. MCTAVISH D, SORKIN EM. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 1991; 42: 65-89.
21. a.
22. DAVIDSON M, MCFINNEY J, STEIN E, SCHROTT H, BAKKER-ARKEMA R, FAYYAD R ET AL. For the Atorvastatin Study Group I. Comparison of the one year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol 1997; 79: 1475-9.
23. JONES P, KAFONEK S, LAURORA I, HUNNINGHAKE D. For the Curves Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the Curves study). Am J Cardiol 1998; 81: 582-7.
24. GOLDSTEIN JL, BROWN MS. Progress in understanding the LDL receptor and HNG-CoA reductase, two membrane proteins that regulate the plasma cholesterol. J Lipid Res 1984; 25: 1450-4.
25. MENÉNDEZ R, FERNÁNDEZ I, DEL RÍO A, GONZÁLEZ RM, FRAGA V, AMOR AM ET AL. Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts. Biol Res 1994; 27: 199-203.
26. HERNÁNDEZ R, FRAGA V, SOTOLONGO V, AMOR AM, DEL RÍO A, GONZÁLEZ RM ET AL. Efecto de la administrución oral de policosanol sobre el metabolismo lipídico de ratas normocolesterolémicas. Rev Mex Ciencias Farmacéuticas 1993; 24: 16-8.
27. HERNÁNDEZ F, ILLINAIT J, MAS R, CASTAÑO G, FERNÁNDEZ L, GONZALEZ M ET AL. Effect of ateromixol (policosanol) on serum lipids and lipopproteins in healthy volunteers. Curr Ther Res 1992; 51: 1-8.
28. ANEIROS E, CALDERÓN B, MAS R, CASTAÑO G, FERNÁNDEZ L, FERNÁNDEZ JC. Effects of successive dose increases of policosanol on the lipid profile and tolerability of treatment. Curr Ther Res 1993; 54: 304-12.
29. CASTAÑO G, TULA L, CANETTI M, MAS R, ILLINAIT J, FERNÁNDEZ L ET AL. Effects of policosanol in hypertensive patients with type II hypercholesterolemia. Curr Ther Res 1996; 57: 691-9.
30. ZARDOYA R, TULA L, CASTAÑO G, MAS R, ILLINAIT J, FERNÁNDEZ JC ET AL. Effects of policosanol on hypercholesterolemic patients with disturbances on serum biochemical indicators of hepatic function. Curr Ther Res 1996; 57: 568-77.
31. ALEMÁN CL, MAS R, HERNÁNDEZ C, RODEIRO I, CEREJIDO E, CAPOTE A ET AL. A 12 months study of policosanol oral toxicity in Sprague-Dawley rats. Toxicol Lett 1994; 70: 77-87.
32. MESA AR, MAS R, NOA M, HERNÁNDEZ C, RODEIRO I, GAMEZ R ET AL. Toxicity of policosanol in Beagle dogs: one year study. Toxicol Lett 1994; 73: 81-90.
33. NATIONAL HIGH BLOOD PRESSURE EDUCATION PROGRAM WORKING GROUP REPORT ON PRIMARY PREVENTION OF HYPERTENSION. National high blood pressure education program. Bethesda 1993, NIH publication No 93-2669.
34. FRIEDEWALD WT, LEVY RI, FRIEDERICKSON SD. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without of the preparative ultracentrifugue. Clin Chem 1972; 18: 499-502.
35. ROMÁN O, PINO ME, VALENZUELA MA. Effects of pindolol and clopamide on blood lipids in arterial hypertensive patients. Cardiology 1987; 74: 219-25.
36. a): 64-70.
37. ALLAIN CHL, POON LS. Enzymatic determination of total serum cholesterol and hypertensive drugs. Clin Chem 1974; 20: 470-5.
38. TIFFANY TO, MORTON JM, HALL EM, GARRETT AS. Clinical evaluation of kinetic enzymatic fixed time and integral analysis of serum triglycerides. Clin Chem 1974; 20: 477-80.
39. LÓPEZ MF, STONE P, ELLIS S, COLWELL JA. Cholesterol determination in high density lipoproteins separated by three different methods. Clin Chem 1977; 23: 882-4.
40. WAUGH AE. Elements of statistical methods. MacGraw-Hill Book 1952 NY.
41. PONS P, RODRÍGUEZ M, ROBAINA C, ILLNAIT J, MAS R, FERNÁNDEZ L ET AL. Effects of succesive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. Int J Clin Pharmacol Res 1994; 14: 27-33.
42. TORRES O, AGRAMONTE AJ, ILLNAIT J, MAS R, FERNÁNDEZ L, FERNÁNDEZ JC. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 1995; 18: 393-7.
43. WALKER JF. Simvastatin: the clinical profile. Am J Med 1989; 87: 44S-48S.
44. BOCUZZI SJ, KEEGAN ME, HIRSH LJ, SHAPIRO DR, PLITKIN DJ, MITCHEL YB. Long-term experience with simvastatin. Drug Invest 1993; 5: 135-40.
45. STALENHOFF ARH, MARC JTM, STUITT PMJ. Efficacy and tolerability of simvastatin. Am J Med 1989; 87 (Suppl 4A): 4A395-4A435.
46. MOLGAARD J, LUNDH BJ, VON SCHENCK H. Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolemia. Atherosclerosis 1991; 91: S21-S28.